Abstract
Objective To observe the clinical efficacy of NVB combined with cisplatin for patients with advanced breast cancer after anthracycline chemotherapy. Methods 60 cases of advanced breast cancer after anthracycline chemotherapy, admitted into our hospital from Sep 2010 to Aug 2011, were randomly divided into 2 groups： 30 patients in a test group got the treatment of NVB combined with cisplatin; 30 patients of the control group continued use of anthracycline chemotherapy. The treatment efficacy was calculated and observed.Results Effective rate （CR ＋ PR） in test group was 43.3%, which was higher than that （13.3%）in the control group, and the difference was statistically significant （P〈0.05）. After 3 courses of treatment, all patients had no severe liver functional damage occurred, and the main drug toxicity manifested as bone marrow suppression, gastrointestinal reactions, and hair loss; in addition, a small number of patients showed peripheral neurotoxicity and phlebitis; the difference of bone marrow suppression between 2 groups was statistically significant （P〈0.05）.Conclusion The treatment of NVB combined with eisplatin for the patients with advanced breast cancer after anthracycline chemotherapy is the best choice, which should be widely applied. Key words: Vinca alkali; Cisplatin; Breast cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
